Denali Therapeutics (NASDAQ:DNLI) Sets New 52-Week High – What’s Next?
by Tristan Rich · The Markets DailyDenali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) reached a new 52-week high during trading on Wednesday . The company traded as high as $25.31 and last traded at $24.77, with a volume of 1658265 shares. The stock had previously closed at $24.05.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the stock. BTIG Research reiterated a “buy” rating and set a $39.00 price objective on shares of Denali Therapeutics in a report on Monday, May 11th. The Goldman Sachs Group upped their target price on shares of Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Deutsche Bank Aktiengesellschaft set a $31.00 target price on shares of Denali Therapeutics in a research report on Friday, May 22nd. Sanford C. Bernstein reiterated a “hold” rating on shares of Denali Therapeutics in a report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.25.
Get Our Latest Research Report on Denali Therapeutics
Denali Therapeutics Trading Up 3.0%
The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.28 and a current ratio of 9.28. The company’s fifty day simple moving average is $20.30 and its 200-day simple moving average is $19.66. The company has a market capitalization of $3.93 billion, a P/E ratio of -8.60 and a beta of 1.03.
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. During the same quarter in the previous year, the company posted ($0.78) EPS. Research analysts predict that Denali Therapeutics Inc. will post -2.77 earnings per share for the current year.
Hedge Funds Weigh In On Denali Therapeutics
Large investors have recently bought and sold shares of the business. Headlands Technologies LLC purchased a new stake in Denali Therapeutics during the second quarter worth $26,000. Johnson Financial Group Inc. purchased a new position in shares of Denali Therapeutics in the 3rd quarter valued at $29,000. State of Wyoming purchased a new position in shares of Denali Therapeutics in the 2nd quarter valued at $29,000. Fifth Third Bancorp bought a new position in shares of Denali Therapeutics in the 1st quarter worth $55,000. Finally, Aster Capital Management DIFC Ltd purchased a new stake in shares of Denali Therapeutics during the 4th quarter worth $57,000. Institutional investors own 92.92% of the company’s stock.
About Denali Therapeutics
Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.